Notice of extraordinary general meeting 21.11.2019

An extraordinary general meeting of Gentian Diagnostics AS, reg. no 983 860 516 (the "Company"), will be held at the Company's offices in:

Bjørnåsveien 5

1596 Moss

21 November 2019 at 10:00 CET

The general meeting will be opened by the chairman of the board, Tomas Settevik, or a person authorized by him, who will make a record of attending shareholders. The board of directors proposes the following agenda:

The Company's nomination committee proposes that Runar Vatne is elected as a new board member in the Company as of 1 December 2019. Further information is included in the nomination committee's proposal, which is made available at the Company's website www.gentian.no.

Shareholders are entitled to attend the general meeting, either in person or by proxy of their own choosing, and to vote for shares as registered in the Norwegian Central Security Depository (VPS) as of the date of the general meeting (shareholders in the Company as of 19 November 2019, as registered in the VPS on 21 November 2019). Shareholders are urged to submit a registration form per mail to Gentian Diagnostics AS, PO Box 733, 1509 Moss, or by e-mail invest@gentian.no. Shareholders wishing to be represented and to vote by proxy at the general meeting may submit a proxy authorization to Gentian Diagnostics AS, PO Box 733, 1509 Moss, or by e-mail invest@gentian.no. Shareholders may appoint proxies with voting instructions. The proxy authorization form may also be brought to the general meeting. The registration and proxy authorization forms are enclosed with this notice as appendix 1 and 2.

Each share in the Company carries one vote at the general meeting and all shares have equal rights. At the date of this notice, the Company has 15,395,921 shares registered in the Norwegian Central Security Depository (VPS), each with a nominal value of NOK 0.10. The Company does not own any shares in the Company.

Shareholders may suggest resolutions for the items on the agenda and may ask that the board members and the general manager provide the necessary information on matters that may affect the evaluation of the items that have been presented to the shareholders for decision, the financial position of the Company and other items up for consideration by the general meeting. This does not apply if the information required cannot be provided without disproportionate harm to the Company, cf. Section 5-15 of the Norwegian Limited Liability Companies Act.

In accordance with section 8 of the Company's articles of association, the proposal from the nomination committee has been made available at the Company's website www.gentian.com and, thus, is not distributed to shareholders together with the notice. However, shareholders have the right to have such documents sent to them upon request to the Company.

Questions regarding the notice, document requests or other inquires can be directed to:

Gentian Diagnostics AS,
CFO Njaal Kind,

Telephone: + 47 919 06 525.